Bio-Path Holdings, Inc.

NasdaqCM:BPTH Stock Report

Market Cap: US$4.6m

Bio-Path Holdings Future Growth

Future criteria checks 0/6

Bio-Path Holdings is forecast to grow earnings and revenue by 58.3% and 72.9% per annum respectively while EPS is expected to grow by 53.6% per annum.

Key information

58.3%

Earnings growth rate

53.6%

EPS growth rate

Biotechs earnings growth26.7%
Revenue growth rate72.9%
Future return on equityn/a
Analyst coverage

Low

Last updated15 Nov 2024

Recent future growth updates

Recent updates

We're Keeping An Eye On Bio-Path Holdings' (NASDAQ:BPTH) Cash Burn Rate

Nov 05
We're Keeping An Eye On Bio-Path Holdings' (NASDAQ:BPTH) Cash Burn Rate

Bio-Path GAAP EPS of -$0.42 beats by $0.07

Aug 16

Is Bio-Path Holdings (NASDAQ:BPTH) In A Good Position To Deliver On Growth Plans?

Jul 08
Is Bio-Path Holdings (NASDAQ:BPTH) In A Good Position To Deliver On Growth Plans?

Here's Why We're Not Too Worried About Bio-Path Holdings' (NASDAQ:BPTH) Cash Burn Situation

Mar 24
Here's Why We're Not Too Worried About Bio-Path Holdings' (NASDAQ:BPTH) Cash Burn Situation

Bio-Path Holdings (NASDAQ:BPTH) Is In A Good Position To Deliver On Growth Plans

Aug 17
Bio-Path Holdings (NASDAQ:BPTH) Is In A Good Position To Deliver On Growth Plans

We Think Bio-Path Holdings (NASDAQ:BPTH) Needs To Drive Business Growth Carefully

Mar 26
We Think Bio-Path Holdings (NASDAQ:BPTH) Needs To Drive Business Growth Carefully

Will Bio-Path Holdings (NASDAQ:BPTH) Spend Its Cash Wisely?

Dec 11
Will Bio-Path Holdings (NASDAQ:BPTH) Spend Its Cash Wisely?

Dosing underway in Bio-Path's early-stage BP1002 study

Nov 19

Bio-Path EPS beats by $0.07

Nov 13

Earnings and Revenue Growth Forecasts

NasdaqCM:BPTH - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/2027N/A-12N/AN/A1
12/31/2026N/A-11N/AN/A1
12/31/2025N/A-11N/AN/A1
12/31/2024N/A-10N/AN/A1
9/30/2024N/A-11-10-10N/A
6/30/2024N/A-12-9-9N/A
3/31/2024N/A-14-9-9N/A
12/31/2023N/A-16-12-12N/A
9/30/2023N/A-17-15-15N/A
6/30/2023N/A-17-15-15N/A
3/31/2023N/A-16-16-16N/A
12/31/2022N/A-14-15-15N/A
9/30/2022N/A-14-13-13N/A
6/30/2022N/A-13-12-12N/A
3/31/2022N/A-11-11-11N/A
12/31/2021N/A-10-10-10N/A
9/30/2021N/A-9-10-10N/A
6/30/2021N/A-10-9-9N/A
3/31/2021N/A-10-10-10N/A
12/31/2020N/A-11-11-11N/A
9/30/2020N/A-11-11-11N/A
6/30/2020N/A-10-10-10N/A
3/31/2020N/A-10-9-9N/A
12/31/2019N/A-9-8-8N/A
9/30/2019N/A-8-7-7N/A
6/30/2019N/A-9-7-7N/A
3/31/2019N/A-8-6-6N/A
12/31/2018N/A-9-6-6N/A
9/30/20180-9-7-7N/A
6/30/20180-8N/A-7N/A
3/31/20180-10N/A-8N/A
12/31/20170-8N/A-8N/A
9/30/20170-7N/A-7N/A
6/30/20170-6N/A-8N/A
3/31/20170-5N/A-8N/A
12/31/20160-7N/A-8N/A
9/30/2016N/A-7N/A-8N/A
6/30/2016N/A-7N/A-7N/A
3/31/2016N/A-6N/A-6N/A
12/31/2015N/A-5N/A-5N/A
9/30/2015N/A-6N/A-5N/A
6/30/2015N/A-5N/A-5N/A
3/31/2015N/A-5N/A-5N/A
12/31/2014N/A-5N/A-4N/A
9/30/2014N/A-4N/A-3N/A
6/30/2014N/A-4N/A-3N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: BPTH is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: BPTH is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: BPTH is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: BPTH is forecast to have no revenue next year.

High Growth Revenue: BPTH is forecast to have no revenue next year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if BPTH's Return on Equity is forecast to be high in 3 years time

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/08 05:12
End of Day Share Price 2025/01/08 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Bio-Path Holdings, Inc. is covered by 5 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jason KolbertMaxim Group
Pamela BassettMaxim Group
Raghuram SelvarajuRodman & Renshaw, LLC